Abstract:OBJECTIVE:To explore the clinical effect of L-ornithine L-aspartate (LOLA) granules in treating chronic liver disease in patients with high-level serum gamma-glutamyltransferase (G-GT) using a 24-week treatment course.METHODS:Two-hundred patients with chronic liver disease and above normal G-GT were given a 12-week course of LOLA granules (9 g/d) and then classified into the following three groups according to the change in serum Gamma-GT:group I:patients with Gamma-GT level returned to normal;group II:patients with serum Gamma-GT level that was reduced during the treatment; group III:patients with serum Gamma-GT level that did not decrease or that increased to a higher level than at start of treatment.After the 12-week treatment course, the patients in group I were divided into three subgroups for receipt of a control drug (compound glycyrrhizin, 50mg/d) or an additional 12-week course of Gamma-GT at a reduced dose (LOLA granules 3 g/d) or at the original dose; groups II and III were maintained on the initial dose for an additional 12 weeks.The groups were reassessed at the end of the second 12-week course (at the end of week 24 of the study's observation period).Count data were compared using the x2 test and measurement data were compared using the t-test.RESULTS:In group I, the serum Gamma-GT level was 90.9% at the end of the first 12-week course and dropped to a mean level of 52.2% for both of the subgroups that received the reduced and original dose after the additional 12 weeks of LOLA granules treatment; the difference from week 12 to week 24 was significant (x2=8.213, P less than 0.05).The 24-week change in serum Gamma-GT levels for the group I reduced and original dose subgroups vs.the control subgroup were also significantly different from those seen in groups II and III (P less than 0.05).The percentage of patients in group I who achieved normal level serum Gamma-GT after 24 weeks of treatment (78.6%) was significantly higher than that for the control group (vs.55.0%, x2=11.452, P less than 0.05).When the patients in group 1 who had received the 12 additional weeks of LOLA granules treatment were measured again at two weeks after the treatments had been discontinued (end of week 26), the percentage of patients with normal serum Gamma-GT level was 92.7%, with only three cases showing obviously abnormal levels; in contrast, the group I patients in the control group of the second 12-week study period had on 66.7% of patients with normal-level serum Gamma-GT.The difference in change between the treated groups (both reduced and original dose) and the control group was significant (x2=14.964, P less than 0.05).CONCLUSION:Patients whose serumGamma-GT levels returned to normal after receipt of LOLA granules for 12 weeks benefitted from an additional 12 weeks of consolidation treatment, and those given the treatment at the original dose benefitted most.Compared with the compound glycyrrhizin, LOLA granules provided a better maintenance of resolved Gamma-GT level.Therefore, the effect of LOLA appears to be reliable and stable as well as safe for clinical use.

Effect of Reduced Glutathione in Treatment of Non-alcoholic Fatty Liver Disease

Effect of Reduced Glutathione Combined with Metformin in the Treatment of Non-Alcoholic Fatty Liver Disease

The application of reduced glutathione in the treaatment of severe pneumonia

Effect of L-ornithine L-aspartate Granules in Treating Chronic Liver Disease in Patients with High-Level Serum Gamma-Glutamyltransferase

Meta Analysis of the Curative Effect of Reduced Glutathione in the Treatment of Liver Injury Caused by Anti-tuberculosis Drugs

Effect of Reduced Glutathione on Cardiac Function of Diabetic Cardiomyopathy in Rats

Enhancement of Antioxidant Capability of Cancer Patients During Chemotherapy by Reduced Glutathione

The Clinical Studies on the Safety and Efficacy of Glutathione for Injection for Patients with Chronic Viral and Toxic Hepatitis

[Aspartate-Ornithine Granules in the Treatment of Nonalcoholic Steatohepatitis: a Multiple-Dose Parallel Controlled Clinical Trial].

Effect of Xuezhikang Combined with Silibinin on Serum Lipids of Fatty Liver Patients

Reduced Glutathione for Prevention of Renal Outcomes in Patients Undergoing Selective Coronary Angiography or Intervention.

Glutathione: Pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease

Study on clinical effect of Yiqi Yangyin and Huoxue Prescription imposed on fatty liver in type 2 diabetes mellitus

Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease.

Effect of Combined Prescription of Linggui Zhugan Tang and Yinchenhao Tang on Nrf2/ARE Signaling Pathway in Rats with Non-alcoholic Steatohepatitis

Randomised post-test-only study of glutathione and ursodeoxycholic acid combination therapy on liver function in cholestasis-induced rats

Effect of Glutathione Support on Changes of Perioperative Amino Acids Profile in Patients with Gastric Cancer

[Inhibitory Effects of Reduced Glutathione Sodium on Renal Nuclear Factor-Kappab Expression in Rats with Diabetes of Different Stages].

Efficacy and safety of Qushi Huayu, a traditional Chinese medicine, in patients with nonalcoholic fatty liver disease in a randomized controlled trial

The effect of reduced L-glutathione supplementation on TNF-α, hs-CRP, and neutrophil-lymphocyte ratio in maintenance hemodialysis patients

Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease†